Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to ...

Only a couple of years since the first sickle cell disease (SCD) gene therapies gained U.S. FDA approval, researchers are working to expand access for younger children, and to improve manufacturing ...

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic ...

The overexpression of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) is tied to poor prognosis in several cancer ...

The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth ...

Receptor-interacting protein kinase 1 (RIPK1) helps promote the survival of cancer cells, and degrading it can sensitize ...

Crescent Biopharma Inc. has announced a new partnership with Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. and reported ...

After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge ...

The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome ...

Roche AG received regulatory clearance from the U.S. and European authorities for a new diagnostic test that detects ...

Saluda Medical Pty Ltd. announced a AU$231 million ($152.7 million) initial public offering on the Australian Securities ...

Drug developers big and small are pursuing a solution for the curse of psychosis that occurs along with the already tragic ...